69 results about "Obesity prevention" patented technology

Methods for enhancing weight loss, or preventing or treating obesity or other conditions related thereto, such as diabetes, involve administering a GLP-1 agonist together with, or prior to, administering a mitochondrial uncoupler. Use of the uncoupler increases weight loss and enhances treatment of obesity and obesity-related medical conditions, such as by preventing weight regain after cessation of administration of the GLP-1 agonist.

The invention relates to the technical field of food nutrition and health care and biological medicines, in particular to application of beta-1, 3 / alpha-1, 3-glucan in preparation of medicines for treating and / or preventing obesity and / or body weight super-severe illness and digestion-aiding health food. According to the experimental results, high-glucose and high-fat rats are continuously fed in the stomach for 8 weeks, and the food intake can be effectively reduced and the body weight can be reduced through preventive administration; the conclusion that beta-1, 3 / alpha-1, 3-glucan has the digestion-aiding health-care food function can be obtained according to the requirements of'health-care food function inspection and evaluation method (2023 edition) by combining the research results that beta-1, 3 / alpha-1, 3-glucan has the stimulation effect on small intestine peristalsis, promotes the growth of intestinal beneficial bacteria and regulates intestinal health in the existing research. The invention provides a new direction for preparing the medicine for treating and / or preventing obesity and / or body weight super-severe illness and health-care food beneficial to digestion.

Provided herein, in part, is a method of treating or preventing obesity or an obesity-related disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a small molecule inhibitor of an Activin receptor Type II.

The invention relates to an application of Edwardsiella fish-sourced protein EseO or a coding gene thereof in preparation of medicines for treating and / or preventing obesity. The edwardsiella fish source protein EseO screened by the invention can inhibit lipid metabolism of cells HeLa and mice C57 / BL6J, which proves that the edwardsiella fish source protein EseO has an obvious fat reducing effect and can be applied to feed additives, medical products and the like in the aquaculture industry related to weight loss.

One aspect of the present invention relates to: a conjugate comprising a peptide of a novel sequence and glycyrrhizin; and a pharmaceutical composition for preventing or treating obesity, the composition comprising the conjugate. The conjugate and composition comprising same according to one aspect were found to inhibit hypertrophy of fat cells, increase the cell membrane expression level of ATP-binding cassette transporter A1 (ABCA1), and reduce the secretion of tumor necrosis factor-α (TNF-α). In addition, the conjugate and composition comprising same were found to remain in a greater amount in the blood and have better pharmacokinetic properties than glycyrrhizin used by itself, and thus can be used in the obesity prevention and / or treatment market / industry.

This disclosure provides a vaccine including a peptide with the amino acid sequence of SEQ ID NO:1; a nucleotide having the sequence of SEQ ID NO:2; or a ribonucleotide having the sequence of SEQ ID NO:3. In certain embodiments, the vaccine further comprises a buffer and / or an adjuvant.

The present disclosure relates to improved GLP-1 receptor agonist polypeptides and molecules comprising these improved GLP-1 receptor agonist polypeptides, such as molecules comprising one or more GLP-1 receptor agonist polypeptides conjugated to an anti- gastric inhibitory peptide receptor (GIPR) antibody. The present disclosure is also directed to the use of these improved GLP-1 receptor agonist polypeptides and conjugate molecules comprising these polypeptides for treating or preventing obesity, an obesity related condition, type 2 diabetes, and / or a type 2 diabetes related condition.

There is herein provided a pharmaceutical formulation comprising one or more compounds that are β2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, and β3-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable excipient, for use in the treatment or prophylaxis of obesity and other medical uses.

To solve the following problem that: there is a need for small molecule agonists of GLP-1 receptors with oral bioavailability, since GLP-1 and GLP-1 receptor agonists may lack sufficient oral bioavailability to be considered as peptide-based oral drugs.SOLUTION: The compound of the present invention is a novel compound having excellent GLP-1 agonist activity and an excellent DMPK profile, and is useful as an agent for treating or preventing various metabolic diseases such as obesity, diabetes, or hyperlipidemia, an isomer thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method for preparing the compound.SELECTED DRAWING: None

The invention discloses application of lactobacillus fermentum E1 in preparation of fat-reducing and weight-losing products, and belongs to the technical field of microorganisms. The lactobacillus fermentum E1 disclosed by the invention can remarkably promote fat metabolism in the zebra fish body in vivo, can remarkably reduce the content of triglyceride and total cholesterol in the hyperlipidemia zebra fish body, and has the potential of being applied to losing weight and regulating the blood fat level; theoretical reference and guidance basis are provided for developing probiotic preparations for treating or preventing obesity and hyperlipidemia by using the lactobacillus fermentum E1.

The present invention relates to a crystalline form I represented by Formula 1, which may be characterized by XRD patterns, DSC profiles, and / or TGA profiles, a method for preparing the same, and a pharmaceutical composition comprising the same, useful for the treatment of prevention of obesity, diabetes, inflammation, or erectile dysfunction. (see formula 1) wherein R1 is C2-C5 alkyl.

A composition comprising a soy protein isolate, a soy fibre, a phospholipid, and a carbohydrate for use in the treatment or prevention of obesity, type 2 diabetes or cardiovascular disorders, wherein the composition is administered together with a first pharmaceutical composition comprising an appetite suppressant agent.

The present invention provides a compound represented by formula (I) or formula (II), or a pharmaceutically acceptable salt, prodrug, stereoisomer, stereoisomer mixture, tautomer, deuterated compound, hydrate or solvate thereof, and a use thereof. The compound has a good agonistic effect on APJ receptors, and can be used for treating and / or preventing diseases such as obesity, hypertension, pulmonary hypertension, and sarcopenia.

The invention provides a compound as shown in a formula (I) or pharmaceutically acceptable salt, prodrug, stereoisomer, tautomer, deuterated compound, hydrate or solvate thereof, and a preparation method and application of the compound or the pharmaceutically acceptable salt, prodrug, stereoisomer, tautomer, deuterated compound, hydrate or solvate thereof. The compound has a good agonistic effect on an APJ receptor, and can be used for treating and / or preventing obesity, hypertension, pulmonary arterial hypertension, sarcopenia and other diseases.

The present invention relates to RNAi constructs for reducing expression of the CNR1 gene. Methods of using such RNAi constructs to reduce visceral adiposity and treat or prevent obesity and obesity-related conditions, such as type 2 diabetes, fatty liver disease, steatohepatitis, and cardiovascular disease, are also described.

The invention discloses application of lactobacillus gasseri LS03 in preparation of fat-reducing and weight-losing products, and belongs to the technical field of microorganisms. The lactobacillus gasseri LS03 disclosed by the invention can remarkably promote fat metabolism in a zebra fish body in vivo, can remarkably reduce the content of triglyceride and total cholesterol in a hyperlipidemia zebra fish body, has the potential of being applied to losing weight and regulating the blood fat level, and can be used for preventing and treating hyperlipidemia. The lactobacillus gasseri LS03 provides theoretical reference and guidance basis for developing probiotic preparations for treating or preventing obesity and hyperlipidemia by utilizing the lactobacillus gasseri LS03.

The present invention provides a novel method that can improve or maintain muscle quantity or muscle strength, and a novel method that can prevent obesity, or lower body fat percentage, or lower body fat quantity, or lower fat removal quantity. The proteoglycan used in the present invention is obtained by a method for producing the proteoglycan, comprising the steps of immersing a biological sample comprising the proteoglycan in an aqueous solution of a surfactant and collecting the solution after the immersion.

The present disclosure is directed to methods of treating or preventing obesity with a luteinizing hormone receptor agonist. More particularly, provided herein are methods of treating obesity in a subject in need thereof, comprising administering to the subject in need thereof a thieno[2,3-d]pyrimidine derivative.

The present invention relates to compounds which are for use in the treatment, alleviation or prevention of obesity and / or a disease, disorder or abnormality associated therewith. In a further embodiment, the compounds are for use in reducing neuroinflammation, reducing microgliosis, and / or improving insulin sensitivity, preferably in an obese subject. In another embodiment, the compounds are for use in the treatment, alleviation or prevention of a disease, disorder or abnormality which is responsive to the modulation of IL-17A and / or IL36G. The compounds are NLRP3 inflammasome pathway inhibitors. In particular, the compounds inhibit the activation of a component of the NLRP3 inflammasome pathway. More particularly, the component of the inflammasome pathway is NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome, in particular IL-1 beta and / or IL-18 levels are modulated thereby.

To provide polypeptide-containing pharmaceutical compositions.SOLUTION: The invention relates to a pharmaceutical composition comprising a polypeptide, more specifically, a pharmaceutical composition for preventing or treating obesity, diabetes or non-alcoholic fatty liver disease. Th pharmaceutical composition is safe without any side effects such as nausea or vomiting with effects of reducing food intake, enhancing insulin secretion, suppressing gastric emptying, promoting lipolysis, and lowering a level of triglycerides. The invention relates to a polypeptide-containing pharmaceutical composition, medical use of the polypeptide-containing pharmaceutical composition, for example, use in treatment or prevention of obesity, diabetes or non-alcoholic fatty liver disease.SELECTED DRAWING: None

The utility model discloses a dog food putting device, which relates to the technical field of automation control, and comprises a bottom plate, the outer wall of the top of the bottom plate is fixedly connected with a fixing frame, a plurality of grooves are arranged in the fixing frame, the inner wall of the bottom of the bottom plate is fixedly connected with a plurality of putting pipelines, and the putting pipelines are communicated with the grooves. According to the dog food feeding device, through the discharging pipe, when the discharging pipe and the storage tank are completely separated, the baffle on the discharging pipe can gradually seal the storage tank, dog food in the storage tank is prevented from being scattered, then the cover plate and the discharging pipe are in a separated state, and the dog food can be fed into the discharging pipe. According to the automatic feeding device for the dog food, the dog food which falls into the discharging pipe from the storage tank falls into the feeding pipeline from the groove and then falls into the discharging box, so that the effect of automatically feeding the dog food is achieved, the situation that too much or too little feeding possibly occurs due to manual feeding is avoided, the healthy body weight of the dog can be maintained, and the problems of obesity or malnutrition and the like can be prevented.

Provided is use of an MDM2 inhibitor in weight management by inducing weight loss in a subject, as well as the MDM2 inhibitor in the treatment and / or prevention of obesity, dyslipidemia, a non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and / or type 2 diabetes. The present invention further relates to a method for using the MDM2 inhibitor in the use.

The present disclosure provides recombinantly manufactured fusion proteins comprising a GLP-1 protein fragment or an analog thereof linked to a feline Fc fragment. Embodiments include the administration of the fusion proteins to patients and their use as an appetite suppressant, for treatment of obesity, for prevention of obesity, or for treatment of other conditions associated with excess weight in cats. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The present invention provides a device and method for preventing obesity and regulating body weight using non-invasive blood glucose measurement, the device comprising: a sensing unit that generates lifestyle pattern biological information by detecting motion sensing information and body information; a storage unit that stores biological information, motion standard model information, blood glucose measurement information, and blood glucose measurement synthesis information; a blood glucose measurement unit that measures blood glucose of a user in real time by non-invasive blood glucose measurement to acquire blood glucose measurement information; a personal matching unit that compares the amount of blood glucose measured by the blood glucose measurement unit with blood glucose amount synthesis information stored in the storage unit according to an externally input or preset blood glucose level range and increase / decrease information; a blood glucose level processing unit that outputs a personal matching result in real time using a comparison result of the personal matching unit; and an output unit that outputs the personal matching result output from the blood glucose level processing unit to the outside so that the outside can recognize.

Bacterial species acting as biomarkers for obesity in domesticated cats and / or dogs are disclosed herein. Also disclosed are methods for diagnosing and / or treating cats and / or dogs having obesity or a predisposition to obesity as well as methods of screening for agents to treat or prevent obesity.

The present invention relates to gene expression signatures, as well as methods and kits using said signatures, for predicting or evaluating the predisposition to obesity in a subject. The signature comprises at least GLUL, SFRP4, ITIH5, GPC1, VGLL3 and C1QTNF1 genes. The methods and kits can be used for selecting a subject susceptible to benefit from prevention against obesity.

The compounds and methods of the present disclosure exhibit induce Ucp1 transcription, enhance of mitochondrial respiration, activate protein kinase A, increase lipolysis, and increase p38 MAPK phosphorylation in cells, particularly brown adipocytes and white adipocytes. They also protect primary cardiomyocytes against hypertrophy induced by adrenergic agonists. Such compounds and methods are useful in the treatment and prevention of conditions such as obesity and associated complex metabolic, endocrine, and hemodynamic changes, as well as related conditions as dyslipidemias, cardiovascular disease, and type 2 diabetes.

Presented herein, in certain aspects, are methods of treating or preventing obesity, assisting or inducing weight loss, suppressing apatite, or inhibiting weight gain in a subject by administering a compound of the invention to a subject.

The invention discloses application of bifidobacterium breve NX-5 in preparation of fat-reducing and weight-losing products, and belongs to the technical field of microorganisms. The bifidobacterium breve NX-5 disclosed by the invention can remarkably promote fat metabolism in a zebra fish body in vivo, can remarkably reduce the content of triglyceride and total cholesterol in a hyperlipidemia zebra fish body, and has the potential of being applied to losing weight and regulating the blood fat level; theoretical reference and guidance basis are provided for developing probiotic preparations for treating or preventing obesity and hyperlipidemia by utilizing the bifidobacterium breve NX-5.

The invention discloses application of lactobacillus acidophilus LA-03 in preparation of fat-reducing and weight-losing products, and belongs to the technical field of microorganisms. The lactobacillus acidophilus LA-03 disclosed by the invention can remarkably promote fat metabolism in a zebra fish body in vivo, can remarkably reduce the content of triglyceride and total cholesterol in a hyperlipidemia zebra fish body, has the potential of being applied to losing weight and regulating the blood fat level, and can be used for preventing and treating hyperlipidemia. Theoretical reference and guidance basis are provided for developing probiotic preparations for treating or preventing obesity and hyperlipidemia by using the lactobacillus acidophilus LA-03.